<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659295</url>
  </required_header>
  <id_info>
    <org_study_id>NN304-1677</org_study_id>
    <nct_id>NCT00659295</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate the Safety of Levemir® in Diabetes</brief_title>
  <acronym>PREDICTIVE™</acronym>
  <official_title>A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus: The PREDICTIVE™ Study: Predictable Results and Experience in Diabetes Through Intensification and Control to Target: an International Variability Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Africa, Asia, Europe, Japan and South America. The aim of this
      observational study is to evaluate the incidence of serious adverse reactions (SARs) while
      using Levemir® (insulin detemir) under normal clinical practice conditions.

      Study conducted globally in 26 countries. Some countries participated in the study for only 3
      months (Austria, Brazil, Denmark, Germany, Israel, Lebanon, Slovenia, Russia, and Turkey),
      while others extended their participation to 6 (Belgium/Luxembourg, Czech Republic, Greece,
      India, Italy, Netherlands, Saudi Arabia, South Africa, South Korea, Sweden, Tunisia, and
      United Kingdom/Ireland) and 12 months (Finland, France, and Japan), respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Reactions, Including Major Hypoglycaemic Events</measure>
    <time_frame>Months 0-12</time_frame>
    <description>The incidence of serious adverse reactions (SARs), including major hypoglycaemic events, during 3 months of insulin detemir therapy for all countries participating in the study, and during 6 and 12 months of insulin detemir therapy for some of the participating countries. The three sub-groups were mutually exclusive. Physicians did not report all major hypoglycaemic events as SARs. The values in the SAE table are SARs including only those major hypoglycaemic events that were reported as SARs by physicians.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">51170</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Type 1 diabetes</arm_group_label>
    <description>Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <description>Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin detemir</intervention_name>
    <description>Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.</description>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <arm_group_label>Type 1 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from both general and speciality practice settings who have been deemed
        appropriate to receive Levemir® (insulin detemir) as new treatment and as part of routine
        out-patient care by the prescribing physician.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age according to approved label in each country and physician discretion

          -  Type 1 or 2 diabetes

          -  Recently started treatment with insulin detemir at the discretion of the investigator.
             Before initiation of insulin detemir they should not have been treated with insulin

          -  Selection at the discretion of the physician

        Exclusion Criteria:

          -  Current treatment with Levemir® (insulin detemir)

          -  Previously enrolled in the study

          -  Hypersensitivity to Levemir® (insulin detemir)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Prague</city>
        <zip>16000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Copenhagen S</city>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>FI-02600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Paris La défense cedex</city>
        <zip>92932</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vouliagment</city>
        <zip>16671</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin 2</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44425</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-920</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>202 15</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34335</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Crawley</city>
        <zip>RH11 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>India</country>
    <country>Japan</country>
    <country>Lebanon</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Tunisia</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Dornhorst A, Lüddeke HJ, Honka M, Ackermann RW, Meriläinen M, Gallwitz B, Sreenan S; PREDICTIVE Study Group. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin. 2008 Feb;24(2):369-76.</citation>
    <PMID>18096110</PMID>
  </results_reference>
  <results_reference>
    <citation>Honka M. [Results of the PREDICTIVE project in the Czech Republic]. Vnitr Lek. 2008 Apr;54(4):361-7. Czech.</citation>
    <PMID>18630615</PMID>
  </results_reference>
  <results_reference>
    <citation>Dornhorst A, Lüddeke HJ, Koenen C, Meriläinen M, King A, Robinson A, Sreenan S; PREDICTIVE Study Group. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. Diabetes Obes Metab. 2008 Jan;10(1):75-81. Epub 2007 Nov 22.</citation>
    <PMID>18034846</PMID>
  </results_reference>
  <results_reference>
    <citation>Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract. 2007 Mar;61(3):523-8.</citation>
    <PMID>17313628</PMID>
  </results_reference>
  <results_reference>
    <citation>Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L; PREDICTIVE Study Group. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract. 2008 Apr;62(4):659-65. doi: 10.1111/j.1742-1241.2008.01715.x.</citation>
    <PMID>18324957</PMID>
  </results_reference>
  <results_reference>
    <citation>Lüddeke HJ, Sreenan S, Aczel S, Maxeiner S, Yenigun M, Kozlovski P, Gydesen H, Dornhorst A; PREDICTIVE Study Group. PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab. 2007 May;9(3):428-34.</citation>
    <PMID>17391171</PMID>
  </results_reference>
  <results_reference>
    <citation>Sreenan S, Virkamäki A, Zhang K, Hansen JB; PREDICTIVE study group. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study. Int J Clin Pract. 2008 Dec;62(12):1971-80. doi: 10.1111/j.1742-1241.2008.01939.x. Erratum in: Int J Clin Pract. 2009 Jan;63(1):176-7:178-80.</citation>
    <PMID>19166444</PMID>
  </results_reference>
  <results_reference>
    <citation>Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Curr Med Res Opin. 2008 May;24(5):1417-28. doi: 10.1185/030079908X297295 . Epub 2008 Apr 8.</citation>
    <PMID>18400145</PMID>
  </results_reference>
  <results_reference>
    <citation>Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Adv Ther. 2008 Jun;25(6):567-84. doi: 10.1007/s12325-008-0069-z.</citation>
    <PMID>18568451</PMID>
  </results_reference>
  <results_reference>
    <citation>Hermansen K, Lund P, Clemmensen K, Breum L, Kleis Moller M, Mette Rosenfalck A, Christiansen E; Danish PREDICTIVE study group. 3-Month Results from Denmark within the Globally Prospective and Observational Study to Evaluate Insulin Detemir Treatment in Type 1 and Type 2 Diabetes: The PREDICTIVE Study. Rev Diabet Stud. 2007 Summer;4(2):89-97. Epub 2007 Aug 10.</citation>
    <PMID>17823693</PMID>
  </results_reference>
  <results_reference>
    <citation>Fontaine P, Gin H, Pinget M, Thivolet C, Hanaire H, Robert JJ, Marre M, Venkatanarasimhachar S. Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE. Adv Ther. 2009 May;26(5):535-51. doi: 10.1007/s12325-009-0033-6. Epub 2009 Jun 2.</citation>
    <PMID>19513632</PMID>
  </results_reference>
  <results_reference>
    <citation>Hermansen K, Dornhorst A, Sreenan S. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study. Curr Med Res Opin. 2009 Nov;25(11):2601-8. doi: 10.1185/03007990903262885.</citation>
    <PMID>19739940</PMID>
  </results_reference>
  <results_reference>
    <citation>Niskanen L, Virkamäki A, Hansen JB, Saukkonen T. Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: evidence from the PREDICTIVE study. Diabetes Res Clin Pract. 2009 Nov;86(2):e15-8. doi: 10.1016/j.diabres.2009.08.005. Epub 2009 Sep 10.</citation>
    <PMID>19747748</PMID>
  </results_reference>
  <results_reference>
    <citation>Yenigun M, Honka M. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study. Int J Clin Pract. 2009 Mar;63(3):425-32. doi: 10.1111/j.1742-1241.2008.01973.x.</citation>
    <PMID>19222627</PMID>
  </results_reference>
  <results_reference>
    <citation>Perriello G, Caputo S, De Pergola G, Di Carlo A, Grassi G, Lapolla A, Pata P, Solerte SB, Zaccardi F. Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects. Expert Opin Pharmacother. 2011 Nov;12(16):2449-55. doi: 10.1517/14656566.2011.626766. Erratum in: Expert Opin Pharmacother. 2011 Dec;12(17):2765.</citation>
    <PMID>21988213</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang L, Christensen T, Sun F, Chang J. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study. Value Health. 2012 Jan-Feb;15(1 Suppl):S56-9. doi: 10.1016/j.jval.2011.11.018.</citation>
    <PMID>22265068</PMID>
  </results_reference>
  <results_reference>
    <citation>Sreenan S, Andersen M, Thorsted BL, Wolden ML, Evans M. Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes. Diabetes Ther. 2014 Dec;5(2):447-58. doi: 10.1007/s13300-014-0075-x. Epub 2014 Jul 15.</citation>
    <PMID>25023521</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2008</study_first_submitted>
  <study_first_submitted_qc>April 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2008</study_first_posted>
  <results_first_submitted>June 16, 2011</results_first_submitted>
  <results_first_submitted_qc>July 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2011</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study conducted globally in 26 countries. Some countries participated for only 3 months, while others extended their participation to 6 and 12 months, respectively.</recruitment_details>
      <pre_assignment_details>Subjects with type 1 or type 2 diabetes including newly diagnosed subjects who had never received insulin or an insulin analogue at the prescribing physician's discretion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Type 1 Diabetes</title>
          <description>Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.</description>
        </group>
        <group group_id="P2">
          <title>Type 2 Diabetes</title>
          <description>Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13529"/>
                <participants group_id="P2" count="37641"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10821"/>
                <participants group_id="P2" count="32038"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2708"/>
                <participants group_id="P2" count="5603"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Type 1 Diabetes</title>
          <description>Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.</description>
        </group>
        <group group_id="B2">
          <title>Type 2 Diabetes</title>
          <description>Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13529"/>
            <count group_id="B2" value="37641"/>
            <count group_id="B3" value="51170"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age: 3 months' participation</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Austria, n=331, 430</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.9" spread="13.8"/>
                    <measurement group_id="B2" value="60.8" spread="11.5"/>
                    <measurement group_id="B3" value="52.6" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil, n=962, 1136</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.6" spread="15.5"/>
                    <measurement group_id="B2" value="60.3" spread="12.9"/>
                    <measurement group_id="B3" value="46.2" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark, n=312, 77</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.6" spread="13.3"/>
                    <measurement group_id="B2" value="61.4" spread="10.9"/>
                    <measurement group_id="B3" value="48.7" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany, n=2640, 7526</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" spread="15.7"/>
                    <measurement group_id="B2" value="62.3" spread="10.4"/>
                    <measurement group_id="B3" value="57.8" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel, n=295, 722</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.5" spread="20.0"/>
                    <measurement group_id="B2" value="60.2" spread="11.1"/>
                    <measurement group_id="B3" value="53.3" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lebanon, n=63, 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="10.3"/>
                    <measurement group_id="B2" value="58.2" spread="11.6"/>
                    <measurement group_id="B3" value="50.6" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia, n=1121, 2515</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.5" spread="15.8"/>
                    <measurement group_id="B2" value="58.7" spread="9.8"/>
                    <measurement group_id="B3" value="49.4" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovenia, n=91, 209</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="14.5"/>
                    <measurement group_id="B2" value="59.1" spread="10.0"/>
                    <measurement group_id="B3" value="54.0" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey, n=622, 2132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="15.2"/>
                    <measurement group_id="B2" value="55.9" spread="10.5"/>
                    <measurement group_id="B3" value="49.8" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age: 6 months' participation</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Belgium/Luxembourg, n=330, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.2" spread="15.4"/>
                    <measurement group_id="B2" value="62.4" spread="9.6"/>
                    <measurement group_id="B3" value="47.0" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic, n=861, 820</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" spread="16.8"/>
                    <measurement group_id="B2" value="59.4" spread="10.7"/>
                    <measurement group_id="B3" value="52.2" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece, n=125, 923</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.6" spread="16.3"/>
                    <measurement group_id="B2" value="64.9" spread="11.2"/>
                    <measurement group_id="B3" value="60.9" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India, n=142, 3162</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.4" spread="17.0"/>
                    <measurement group_id="B2" value="52.6" spread="10.1"/>
                    <measurement group_id="B3" value="51.7" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy, n=177, 1297</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="16.0"/>
                    <measurement group_id="B2" value="64.9" spread="9.8"/>
                    <measurement group_id="B3" value="62.5" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands, n=92, 324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.9" spread="16.6"/>
                    <measurement group_id="B2" value="59.7" spread="13.0"/>
                    <measurement group_id="B3" value="55.3" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saudi Arabia, n=104, 503</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.0" spread="13.1"/>
                    <measurement group_id="B2" value="50.0" spread="10.5"/>
                    <measurement group_id="B3" value="45.7" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa, n=207, 247</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.6" spread="16.0"/>
                    <measurement group_id="B2" value="53.3" spread="11.9"/>
                    <measurement group_id="B3" value="44.3" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea, n=224, 8854</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.0" spread="16.0"/>
                    <measurement group_id="B2" value="56.9" spread="12.4"/>
                    <measurement group_id="B3" value="56.4" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden, n=553, 95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.0" spread="17.5"/>
                    <measurement group_id="B2" value="61.3" spread="11.2"/>
                    <measurement group_id="B3" value="44.8" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tunisia, n=21, 316</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.5" spread="15.9"/>
                    <measurement group_id="B2" value="57.6" spread="11.1"/>
                    <measurement group_id="B3" value="55.5" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom/Ireland, n=2292, 1832</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="17.6"/>
                    <measurement group_id="B2" value="59.2" spread="11.7"/>
                    <measurement group_id="B3" value="46.0" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age: 12 months' participation</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Finland, n=809, 249</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.9" spread="14.3"/>
                    <measurement group_id="B2" value="58.8" spread="10.7"/>
                    <measurement group_id="B3" value="45.9" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France, n=641, 1127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="16.1"/>
                    <measurement group_id="B2" value="62.6" spread="11.9"/>
                    <measurement group_id="B3" value="57.0" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan, n=490, 2801</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" spread="16.1"/>
                    <measurement group_id="B2" value="61.9" spread="12.8"/>
                    <measurement group_id="B3" value="60.2" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6865"/>
                    <measurement group_id="B2" value="19175"/>
                    <measurement group_id="B3" value="26040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6658"/>
                    <measurement group_id="B2" value="18453"/>
                    <measurement group_id="B3" value="25111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes (3 months' participation)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Austria, n=330, 428</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.5" spread="13.6"/>
                    <measurement group_id="B2" value="12.5" spread="8.5"/>
                    <measurement group_id="B3" value="15.1" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil, n=959, 1141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.6" spread="9.7"/>
                    <measurement group_id="B2" value="13.7" spread="9.0"/>
                    <measurement group_id="B3" value="13.2" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark, n=312, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.4" spread="12.6"/>
                    <measurement group_id="B2" value="11.8" spread="6.6"/>
                    <measurement group_id="B3" value="18.7" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany, n=2607, 7468</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.2" spread="12.5"/>
                    <measurement group_id="B2" value="10.6" spread="7.2"/>
                    <measurement group_id="B3" value="12.3" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel, n=286, 721</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.3" spread="12.4"/>
                    <measurement group_id="B2" value="15.7" spread="9.1"/>
                    <measurement group_id="B3" value="15.3" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lebanon, n=63, 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.4" spread="7.7"/>
                    <measurement group_id="B2" value="12.2" spread="7.1"/>
                    <measurement group_id="B3" value="12.0" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia, n=1112, 2509</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" spread="8.2"/>
                    <measurement group_id="B2" value="9.5" spread="5.8"/>
                    <measurement group_id="B3" value="9.2" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovenia, n=90, 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.1" spread="13.0"/>
                    <measurement group_id="B2" value="13.7" spread="8.0"/>
                    <measurement group_id="B3" value="15.0" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey, n=612, 2127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="6.7"/>
                    <measurement group_id="B2" value="10.6" spread="6.6"/>
                    <measurement group_id="B3" value="10.1" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes (6 months' participation)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Belgium/Luxembourg, n=329, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.7" spread="12.3"/>
                    <measurement group_id="B2" value="14.0" spread="9.2"/>
                    <measurement group_id="B3" value="17.3" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic, n=856, 807</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" spread="11.1"/>
                    <measurement group_id="B2" value="12.8" spread="7.8"/>
                    <measurement group_id="B3" value="13.7" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece, n=129, 956</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.9" spread="9.9"/>
                    <measurement group_id="B2" value="13.4" spread="7.6"/>
                    <measurement group_id="B3" value="13.2" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India, n=139, 3178</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.6" spread="6.2"/>
                    <measurement group_id="B2" value="8.5" spread="5.5"/>
                    <measurement group_id="B3" value="8.4" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy, n=175, 1292</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.6" spread="11.6"/>
                    <measurement group_id="B2" value="14.7" spread="8.6"/>
                    <measurement group_id="B3" value="14.7" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands, n=88, 318</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.0" spread="14.5"/>
                    <measurement group_id="B2" value="9.6" spread="6.9"/>
                    <measurement group_id="B3" value="11.0" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saudi Arabia, n=96, 494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="6.3"/>
                    <measurement group_id="B2" value="9.1" spread="5.6"/>
                    <measurement group_id="B3" value="8.8" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa, n=196, 243</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.3" spread="9.4"/>
                    <measurement group_id="B2" value="9.9" spread="7.4"/>
                    <measurement group_id="B3" value="10.5" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea, n=214, 8701</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.4" spread="7.7"/>
                    <measurement group_id="B2" value="10.1" spread="6.8"/>
                    <measurement group_id="B3" value="10.1" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden, n=547, 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.6" spread="14.2"/>
                    <measurement group_id="B2" value="13.6" spread="7.4"/>
                    <measurement group_id="B3" value="18.7" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tunisia, n=21, 316</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="7.7"/>
                    <measurement group_id="B2" value="11.5" spread="6.4"/>
                    <measurement group_id="B3" value="11.3" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom/Ireland, n=2260, 1827</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.2" spread="12.3"/>
                    <measurement group_id="B2" value="11.3" spread="7.7"/>
                    <measurement group_id="B3" value="13.5" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes (12 months' participation)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Finland, n=796, 245</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.8" spread="12.3"/>
                    <measurement group_id="B2" value="13.3" spread="7.6"/>
                    <measurement group_id="B3" value="18.3" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France, n=628, 1117</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" spread="12"/>
                    <measurement group_id="B2" value="14.6" spread="8.9"/>
                    <measurement group_id="B3" value="15.5" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan, n=420, 2240</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.1" spread="10"/>
                    <measurement group_id="B2" value="14.2" spread="8.9"/>
                    <measurement group_id="B3" value="13.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Serious Adverse Reactions, Including Major Hypoglycaemic Events</title>
        <description>The incidence of serious adverse reactions (SARs), including major hypoglycaemic events, during 3 months of insulin detemir therapy for all countries participating in the study, and during 6 and 12 months of insulin detemir therapy for some of the participating countries. The three sub-groups were mutually exclusive. Physicians did not report all major hypoglycaemic events as SARs. The values in the SAE table are SARs including only those major hypoglycaemic events that were reported as SARs by physicians.</description>
        <time_frame>Months 0-12</time_frame>
        <population>FAS (Full Analysis Set) consists of all patients with a baseline visit who were prescribed insulin detemir at least once</population>
        <group_list>
          <group group_id="O1">
            <title>Type 1 Diabetes</title>
            <description>Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes</title>
            <description>Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Reactions, Including Major Hypoglycaemic Events</title>
          <description>The incidence of serious adverse reactions (SARs), including major hypoglycaemic events, during 3 months of insulin detemir therapy for all countries participating in the study, and during 6 and 12 months of insulin detemir therapy for some of the participating countries. The three sub-groups were mutually exclusive. Physicians did not report all major hypoglycaemic events as SARs. The values in the SAE table are SARs including only those major hypoglycaemic events that were reported as SARs by physicians.</description>
          <population>FAS (Full Analysis Set) consists of all patients with a baseline visit who were prescribed insulin detemir at least once</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13529"/>
                <count group_id="O2" value="37641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 months sub-group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months sub-group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months sub-group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over 3, 6 and 12 months, respectively, depending on the participating country</time_frame>
      <desc>Full Analysis Set. This is a non-interventional study. According to the primary endpoint/outcome measure, the serious events collected in all countries are Serious Drug Reactions only, and not Serious Adverse Events and other adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Type 1 Diabetes</title>
          <description>Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.</description>
        </group>
        <group group_id="E2">
          <title>Type 2 Diabetes</title>
          <description>Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="13529"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Injection site stinging</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Limp injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Blood glucose decrease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13529"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="73" subjects_affected="66" subjects_at_risk="13529"/>
                <counts group_id="E2" events="34" subjects_affected="33" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia unawareness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coma acidotic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="13529"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Pityriasis rubra pilaris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Transmyocardial revascularisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13529"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13529"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37641"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk acknowledges the physician’s right to publish the entire results of the trial. Any such scientific paper, presentation, communication, or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

